Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncotelic Therapeutcs Inc (OP:OTLC)

0.0366 +0.0016 (+4.57%)
Streaming Delayed Price Updated: 12:09 PM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncotelic Therapeutcs Inc

< Previous 1 2 3 4 5 6 Next >
Oncotelic Therapeutics Inc. (OTLC) Targets Biotech’s Manufacturing Bottleneck with AI-Powered GMP Platform
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Positive Safety Review for Phase 1b Sapu003 Trial
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Launches AI-Powered GMP Manufacturing Services Platform at BIO 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
AINewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Advances Robotics Deployment at SAPU Bio Sterile Manufacturing Facility
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation
Via Investor Brand Network
Topics Artificial Intelligence
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Advanced Cancer Drug Delivery
Via Investor Brand Network
Topics Intellectual Property
News headline image
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
From NetworkNewsWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Drug-Delivery Market Growth
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Sapu003 Phase 1b Program, Appoints Global CRO for International Study Execution
Via Investor Brand Network
Topics Intellectual Property
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies
Via Investor Brand Network
Topics Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
From BioMedWire
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
Via Investor Brand Network
Oncotelic Therapeutics Inc. (OTLC) Holds $388M JV Valuation as Pipeline Momentum Builds
Via Investor Brand Network
TechMediaBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Subsidiary TechForce Deploys Autonomous Lab Robot in Pharmaceutical Automation Milestone
Via Investor Brand Network
News headline image
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
From Nightfood Holdings Inc.
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano to Present Deciparticle(TM) Nanomedicine Platform at BIO International Convention 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
From BioMedWire
Via GlobeNewswire
News headline image
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Oncotelic Therapeutics Inc. (OTLC) Advances CNS Drug Delivery Strategy as BBB Breakthroughs Drive New Biotech Market Opportunity
Via Investor Brand Network
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.